Problemas asociados al uso de digoxina en pacientes geriátricos / Problems associated to the use of digoxin in the elderly patients

OBJETIVO: identificar los problemas asociados al uso de digoxina en pacientes ancianos. MÉTODOS: se seleccionaron los pacientes a partir de los certificados médicos, por digoxina, archivados en las farmacias, y luego de dar su consentimiento de participación se realizaron sucesivas entrevistas. Se tuvo en cuenta enfermedad para la que fue indicado el medicamento, individualización de la prescripción, dosis empleada e intervalo de dosificación prescrito. Se valoró además las prescripciones potencialmente inapropiadas, según criterios de Beers. RESULTADOS: en el 100 % de los pacientes se detectó algún problema asociado al empleo de la digoxina. Entre los problemas detectados estuvieron: interacciones medicamentosas (100 %), probable uso para tratar enfermedades no indicadas (82 %), empleo de dosis superiores a las indicadas (62 %) y uso de intervalo de dosificación irregular (47 %). Entre los fármacos interactuante se detectaron 58 prescripciones potencialmente inapropiadas para el paciente anciano, las cuales representaron el 26,6 % del total de prescripciones. CONCLUSIONES: se detectó alta incidencia de problemas asociados al uso de digoxina en el paciente anciano, por lo que se hace necesario realizar un trabajo conjunto "médico-farmacéutico-paciente" en aras de ganar en calidad de la prescripción y uso de la digoxina en el adulto mayor.

OBJECTIVE: to identify the problems related to the use of digoxin in elderly patients. METHODS: the selection of patients was based on the medical certificates for the use of digoxin, which were filed in the drugstores, and on the patient's consent to be involved in interviews. The research took into account the disease for which digoxin was prescribed as treatment, the individualization of prescription, the prescribed dosage and dosing intervals, in addition to the assessment of potentially inappropriate prescriptions according to Beers criteria. RESULTS: all the participating patients presented with some problems related to the use of digoxin. The most common were drug interactions (100 %), likely use to treat nonprescribed diseases (82 %), use of a dose higher than the recommended one (62 %) and irregular dosing interval (47 %). Among drug interactions were 58 potentially inappropriate prescriptions for elderly patients, which accounted for 26.6 % of total prescriptions. CONCLUSIONS: there was a high incidence rate of problems associated with the use of digoxin in the elderly, so it is necessary to work together, meaning the physician, the pharmacist and the patient, in order to increase prescribing quality for the use of digoxin in the elderly.

Comparação do desfecho entre a cardiopatia chagásica e a miocardiopatia dilatada idiopática / Comparison of outcome between Chagas cardiomyopathy and idiopathic dilated cardiomyopathy

FUNDAMENTO: Pouco se sabe sobre o desfecho dos pacientes com cardiopatia chagásica, em comparação aos pacientes com miocardiopatia dilatada idiopática na era contemporânea. OBJETIVO: Comparar o desfecho dos pacientes chagásicos com insuficiência cardíaca sistólica crônica decorrente da cardiopatia chagásica ao observado em pacientes com MDI na era contemporânea. MÉTODOS: Foi incluído um total de 352 pacientes (246 com cardiomiopatia chagásica e 106 com miocardiopatia dilatada idiopática), seguidos prospectivamente em nossa Instituição, de janeiro de 2000 a janeiro de 2008. Todos os pacientes receberam tratamento clínico contemporâneo padrão. RESULTADOS: Na análise multivariada com o modelo de risco proporcional de Cox, o uso da digoxina (relação de risco = 3,17; intervalo de confiança de 95 por cento, de 1,62 a 6,18; p = 0,001) necessitou de suporte inotrópico (relação de risco = 2,08; intervalo de confiança de 95 por cento, de 1,43 a 3,02; p < 0,005). A fração de ejeção do ventrículo esquerdo (relação de risco = 0,97; intervalo de confiança de 95 por cento, de 0,95 a 0,99; p < 0,005) e a etiologia da cardiopatia chagásica (relação de risco = 3,29; intervalo de confiança de 95 por cento, de 1,89 a 5,73; p < 0,005) foram associadas positivamente à mortalidade, enquanto a terapia com betabloqueadores (relação de risco = 0,39; intervalo de confiança de 95 por cento, de 0,26 a 0,56; p < 0,005) foi associada negativamente à mortalidade. A probabilidade de sobrevida para pacientes com cardiomiopatia chagásica em oito, 24 e 49 meses foi de 83 por cento, 61 por cento e 41 por cento, respectivamente. Já para pacientes com cardiomiopatia dilatada idiopática, foi de 97 por cento, 92 por cento e 82 por cento, respectivamente (p < 0,005). CONCLUSÃO: Na era atual do tratamento da insuficiência cardíaca, os pacientes com cardiomiopatia chagásica têm um desfecho pior em comparação aos pacientes com cardiomiopatia dilatada idiopática.

BACKGROUND: Little is known about the outcome of patients with Chagas cardiomyopathy in comparison to that of patients with Idiopathic Dilated Cardiomyopathy in the contemporary era. OBJECTIVE: To compare the outcome of chagasic patients with chronic systolic heart failure secondary to Chagas cardiomyopathy with that observed in patients with IDC in the contemporary era. METHODS: A total of 352 patients (246 with Chagas cardiomyopathy, 106 with Idiopathic Dilated Cardiomyopathy) prospectively followed at our Institution from January, 2000 to January, 2008 were included. All patients received standard contemporary medical therapy. RESULTS: In Cox proportional hazards model multivariate analysis, digoxin use (Hazard Ratio=3.17; 95 percent Confidence Interval 1.62 to 6.18; p=0.001), need of inotropic support (Hazard Ratio=2.08; 95 percent Confidence Interval 1.43 to 3.02; p<0.005), left ventricular ejection fraction (Hazard Ratio=0.97; 95 percent Confidence Interval 0.95 to 0.99; p<0.005), and Chagas cardiomyopathy etiology (Hazard Ratio=3.29; 95 percent Confidence Interval 1.89 to 5.73; p<0.005) were positively associated with mortality, whereas Beta-Blocker therapy (Hazard Ratio=0.39; 95 percent Confidence Interval 0.26 to 0.56; p<0.005) was negatively associated with mortality. Survival probability for patients with Chagas cardiomyopathy at 8, 24, and 49 months was 83 percent, 61 percent, and 41 percent, respectively, and for patients with Idiopathic Dilated cardiomyopathy 97 percent, 92 percent, and 82 percent, respectively (p<0.005). CONCLUSION: In the current era of heart failure therapy, patients with Chagas cardiomyopathy have a poorer outcome in comparison to patients with Idiopathic Dilated Cardiomyopathy.

Digoxin serum levels in patients with Chagas' cardiomyopathy and heart failure / Níveis séricos de digoxina em pacientes com insuficiência cardíaca secundária à cardiomiopatia da doença de Chagas

INTRODUCTION: The purpose of this study was to determine digoxin serum concentrations in patients with Chagas' cardiomyopathy with chronic heart failure, because little is known concerning this laboratory test in patients with this condition. METHODS: This study focuses on 29 (29 percent) out of 101 patients with chronic heart failure secondary to Chagas' cardiomyopathy receiving digoxin therapy. Digoxin was measured by the immune-enzymatic method. RESULTS: New York Heart Association Functional Class III/IV was noted in 13 (45 percent) patients. The mean potassium serum level was 4.3± 0.5mEq/L, mean creatinine serum levels 1.4± 0.3dg/100ml, and left ventricular ejection fraction 34.7± 13.8 percent. The median digoxin serum level was 1.27 (0.55; 1.79)ng/ml. Sixteen (55 percent) patients had digoxin serum levels higher than 1.0ng/ml. Abnormal digoxin serum levels were verified in 13 (45 percent) patients. Digoxin serum levels correlated moderately with creatinine serum levels (r = 0.39; p< 0.03) and negatively with sodium serum levels (r= -0.38; p= 0.03). CONCLUSIONS: Digoxin serum concentration should be measured in patients with Chagas' cardiomyopathy with chronic heart failure receiving digoxin therapy due to the potential for digoxin toxicity.

INTRODUÇÃO: O propósito deste trabalho foi o de determinar a concentração sérica de digoxina em pacientes com insuficiência cardíaca crônica secundária à cardiomiopatia da doença de Chagas porque pouco se conhece sobre os níveis séricos desse fármaco em pacientes com tal condição clínica. MÉTODOS: Foram recrutados 29 (29 por cento) de 101 pacientes com insuficiência cardíaca crônica secundária à cardiomiopatia da doença de Chagas, os quais estavam sendo tratados com digoxina. Essa droga foi medida no soro desses pacientes pelo método imunoenzimático. RESULTADOS: Treze (45 por cento) pacientes estavam no grau III/ IV da Sociedade Nova-Iorquina de Cardiologia. Os níveis séricos de potássio médio foram 4,3± 0,5 mEq/L, a creatinina sérica média 1,4± 0,3dg/100ml, e a fração de ejeção do ventrículo esquerdo 34.7± 13. 8 por cento. Os níveis séricos médios de digoxina foram 1,27 (0,55; 1,79)ng/ml. Dezesseis (55 por cento) pacientes apresentaram níveis séricos de digoxina > 1,0ng/ml. Níveis séricos anormais de digoxina foram observados em 13 (45 por cento) pacientes. Os níveis séricos de digoxina correlacionaram moderadamente com os de creatinina (r= 0,39; p< 0,03) e negativamente com os de sodium (r= -0,38; p= 0,03). CONCLUSÕES: Os níveis séricos de digoxina devem ser medidos em pacientes com insuficiência cardíaca crônica secundária à cardiomiopatia da doença de Chagas por causa do potencial para ocorrer toxicidade pela digoxina.

Digitálicos: os resultados do DIG no século XXI / Digoxin: the results of the DIG study in the XXI century / Digitálicos: los resultados del DIG en el siglo XXI

Depois da divulgação de que não houve significância estatística na mortalidade geral do estudo DIG, a indicação dos digitálicos nos esquemas de tratamento da insuficiência cardíaca congestiva (ICC) reduziu drasticamente. Estudos post hoc, que reavaliaram os dados do DIG, indicaram que um aspecto não considerado neste ensaio multicêntrico exerce influência decisiva no prognóstico dos pacientes: a concentração sérica da digoxina. Em relação àqueles que receberam placebo, a mortalidade geral e a hospitalização foram reduzidas em pacientes com concentração de digoxina inferior a 0,9 ng/ml. No primeiro trabalho que avaliou a influência dos digitálicos em modelo experimental de ICC, verificamos em nosso laboratório que ratas com síndrome congestiva secundária a infarto do miocárdio têm a sobrevida prolongada sob tratamento com digitoxina. As informações atuais recomendam que os méritos dos digitálicos continuem a ser analisados para estabelecer adequadamente sua importância no tratamento da ICC.

After the report that there was no statistical significance in the general mortality of the DIG study, the indication of digoxin in the treatment regimens for congestive heart failure (CHF) drastically decreased. Post hoc studies that reassessed the DIG study data, indicated that an aspect that was not considered in this multicenter study has a critical influence on the prognosis of patients: the serum levels of digoxin. Regarding those that received a placebo, the general mortality and hospitalization were decreased in patients with a digoxin level < 0.9 ng/ml. At the first study that assessed the influence of digitalis in an experimental model of CHF, we verified in our lab that female rats with congestive syndrome secondary to myocardial infarction have a prolonged survival when undergoing treatment with digitoxin. The current information recommends that the merits of digoxin continue to be analyzed in order to adequately establish its importance in the treatment of CHF.

Después de la divulgación de que no hubo significancia estadística en la mortalidad general del estudio DIG, la indicación de los digitálicos en los esquemas de tratamiento de la insuficiencia cardíaca congestiva (ICC) se redujo drásticamente. Estudios post hoc, que reevaluaron los datos del DIG, indicaron que un aspecto no considerado en este ensayo multicéntrico ejerce influencia decisiva en el pronóstico de los pacientes: la concentración sérica de la digoxina. En relación a aquellos que recibieron placebo, la mortalidad general y la hospitalización fueron reducidas en pacientes con concentración de digoxina inferior a 0,9 ng/ml. En el primer trabajo que evaluó la influencia de los digitálicos en modelo experimental de ICC, verificamos en nuestro laboratorio que ratas con síndrome congestivo secundario a infarto de miocardio tienen la sobrevida prolongada bajo tratamiento con digitoxina. Las informaciones actuales recomiendan que los méritos de los digitálicos continúen a ser analizados para establecer adecuadamente su importancia en el tratamiento de la ICC.

Cardiovascular drugs in human mechanical nociception: digoxin, amlodipine, propranolol, pindolol and atenolol

Calcium channel blockers, β adrenergic receptor blockers and Na/K ATPase inhibitors are widely used drugs, mainly for cardiovascular diseases. Their pharmacological targets are not restricted to the cardivascular tissue, nociceptive system structures also express similar targets, which strongly suggests a direct effect on pain sensation. To evaluate the pain intensity changes in outpatient groups, who receive these drugs as a therapy, a cross-sectional sampled, randomized patient groups receiving the calcium channel blocker amlodipine for blood hypertension (n=45), β adrenergic receptor blockers (propranolol, atenolol or pindolol; n=40) for blood hypertension, or digoxin (n=40) for heart failure, were compared to an aparently healthy volunteers control group (n=60). A calibrated noxious pressure of 890 g/mm² was applied for 5 seconds on the patient’s sternum. Subjective pain intensity was reported by the visual analog scale (VAS, 0 to 10). Pain modulation system was evaluated by the application of a second stimulus with a 5 minutes delay. The analgesic effect of the β blockers group (propanolol, atenolol, pindolol) was dosage-dependant (-36.8 percent; P=0.0000003), without differences among them. The calcium channel blocker amlodipine showed lower pain scores (-50.6 percent; P=0.0000003) than β-receptor blockers (P=0.0000003). Digoxin presented the highest pain scores (+56.5 percent; P=0.0000003). All pain scores for the second stimulus were lower than the first stimulus and were differentially affected by β-blockers (atenolol, pindolol and propanolol) and calcium channel blocker (amlodipine), but not by digoxin. These results suggest the influence of widely clinically used cardiovascular drugs on nociception.

Los bloqueadores de los canales de calcio, los bloqueadores de los receptores β adrenérgicos y los inhibidores de la ATPasa Na/K son medicamentos ampliamente usados en enfermedades cardiovasculares. Sus blancos farmacológicos no se restringen al tejido cardiovascular, el sistema nervioso nociceptivo expresa blancos similares, lo que sugiere fuertemente un efecto directo en la sensación del dolor. El objetivo del presente estudio fue evaluar los cambios en la intensidad del dolor en grupos de pacientes ambulatorios que reciban estos medicamentos como terapia. Grupos aleatorios de pacientes que reciben el bloqueador de canales de calcio amlodipina contra la hipertensión arterial (n=45), bloqueadores de receptores β adrenérgicos (propranolol, atenolol or pindolol; n=40) contra la hipertensión arterial o digoxina (n=40) por insuficiencia cardíaca fueron comparados con un grupo control de voluntarios aparentemente sanos (n=60). A todos los grupos se les aplicó una presión nociva calibrada de 890 g/mm² durante 5 segundos sobre el esternón. El paciente reportó la intensidad subjetiva del dolor mediante la escala visual análoga (VAS). El sistema de modulación descendente del dolor fue evaluado mediante la aplicación del mismo estímulo 5 minutos después del primero. Se determinó un efecto analgésico en el grupo de β bloqueantes (propanolol, atenolol, pindolol) dosis dependiente (-36,8 por ciento; P=0,0000003) sin mostrar diferencias entre ellos. El bloqueador de canales de calcio amlodipina mostró un efecto analgésico (-50,6 por ciento; P=0,0000003) que fue mayor que el de los β bloqueantes (P=0,0000003). El grupo con digoxina expresó un efecto hiperalgésico (+56,5 por ciento; P=0,0000003). Todos los valores de dolor para el segundo estímulo fueron menores que para el primero y fueron diferencialmente afectados por los β bloqueantes (atenolol, pindolol and propanolol) y por la amlodipina pero no por la digoxina. Estos...

Prenatal management with digoxin and sotalol combination for fetal supraventricular tachycardia : Case report and review of literature.

Sustained fetal supraventricular tachycardia (SVT) with a heart rate of approximately 210 bpm may lead to increased atrial and venous pressures and congestive heart failure. There is no clear consensus regarding the best drug-treatment regimens for fetal SVT. However, considerable nonrandomized experience in the transmaternal treatment of fetal SVT is available with a number of antiarrhythmic agents. We report a case of fetal supraventricular tachyarrhythmia with hydrops detected at 32 weeks that was managed with combination of oral digoxin and sotalol and review management guidelines available in the literature.

Asymmetric pulmonary edema after scorpion sting: a case report / Edema pulmonar assimétrico após picada de escorpião: relato de caso

A 12-year-old boy was referred with acute asymmetric pulmonary edema (APE) four-hour after scorpion sting to Emergency department. On admission, the main clinical manifestations were: dyspnea, tachypnea, and tachycardia. Chest x-ray revealed APE predominantly on the right hemithorax. The patient was treated with oxygen, intravenous frusemide and digoxin and discharged on the sixth hospital day in a good condition. This case report emphasizes the occurrence of asymmetric pulmonary edema after severe scorpion envenomation within few hours immediately after the sting.

Menino de 12 anos foi internado no Pronto Socorro, com edema pulmonar assimétrico agudo (APE), quatro horas após picada de escorpião. À admissão, as principais manifestações clínicas foram: dispnéa, taquipnéa e taquicardia. Raio X do pulmão revelou APE predominantemente no hemitórax direito. O paciente foi tratado com oxigênio, frusemida intravenosa e digoxina e teve alta no sexto dia de internação, em boas condições. Este relato de caso enfatiza a ocorrência de edema pulmonar assimétrico algumas horas após a picada.

A rare cause of heart failure--primary hypoparathyroidism.

We report a patient who presented with congestive heart failure (ejection fraction 24.4%) and who had previous history of convulsions. Our investigations found him to be a case of primary hypoparathyroidism. He showed a dramatic response with the addition of calcium infusion therapy with almost full recovery of left ventricular function (67% ejection fraction after 16 days of the initial echo). We conclude that in a young patient a thorough investigation for heart failure is never complete without looking for endocrine and metabolic causes. The prognosis in these cases is much better, identification and treatment of the same will yield dramatic results.

Could garlic be an useful adjuvant therapy in adriamycin heart failure?

50 year old suffering from breast carcinoma, treated with adriamycin developed heart failure with 22.82% ejection fraction. Added garlic pearl to routine anti-failure measures for 9 months to achieve 51.6% ejection fraction.

Taquiarritmias supraventrículares fetales refractarias al tratamiento inicial / Fetal supraventricular tachyarrhythmias refractory to initial therapy

Las arritmias fetales representan un motivo infrecuente de ingreso ala unidad de cuidados intensivos. Se presenta tres casos de gestantes entre 27 y 32 semanas, con el diagnóestico de taquiarritmias supraventriculares fetales sostenidas, que exhibían fracaso en el intento inicial de reversión con digoxina. Dos casos con taquicardia sapraventricular respondieron favorablemente cuando se asoció flecainida. Un feto hidrópico con aleteo auricular y bloqueo 2:1 no revirtió con la associón de flecainida ni amiodarona a la digoxina y requirió la interrupsión de la gestación en la 30 ª semana. El neonato presentó disfunción tiroidea transitória atribuída a la administración de amiodarona.

Flutter auricular fetal con hidrops en embarazo gemelar triple / Foetal atrial flutter with hydrops in a triplet pregnancy

Se presenta un caso de flutter auricular, con bloqueo auriculoventricular 2:1, asociado a hidrops en uno de los fetos de un embarazo gemelar triple, pesquisado por taquicardia fetal y confirmado con ecocardiografía a las 26 semanas de gestación. Se administró digoxina a la madre, sin exito, por lo que agregamos flecainida al decimo tercer dia de tratamiento, logrando conversión a ritmo sinusal y regresión del hidrops dentro del útero. Se discute la utilidad del flecainide como primera linea para este tipo de pacientes y la necesidad de profilaxis antiarritmica postnatal, considerando la favorable evolución en este periodo.

Diagnóstico y manejo de un caso de flutter auricular fetal con hidrops en embarazo gemelar triple / Diagnosis and handling of a case of fetal atrial flutter with hydrops in triplet pregnancy

Presentamos un caso de flutter auricular, con bloqueo auriculoventricular 2:1, asociado a hidrops en uno de los fetos de un embarazo gemelar triple, pesquisado por taquicardia fetal y confirmado con ecocardiografía a las 26 semanas de gestación. Iniciamos digoxina transplancetaria sin éxito por lo que agregamos flecainide al décimo tercer día, logrando conversión a ritmo sinusal y regresión del hidrops in útero. Se discute la utilidad del flecainide como primera línea para este tipo de pacientes y la necesidad de profilaxis antiarrítmica postnatal, considerando la favorable evolución en este período.

A practical approach for the diagnosis and management of dilated cardiomyopathy.

Dilated cardiomyopathy (DCM) refers to a group of conditions of diverse etiology in which both ventricles are enlarged with reduced contractility. Certain correctable conditions associated with ventricular dysfunction can masquerade as DCM. Most of them can be identified with relatively inexpensive and readily available tests. A typical diagnostic work-up for a child with DCM also includes a number of investigations to identify the underlying cause, some of which are expensive and sophisticated. The average center in the developing world often does not have the facilities to carry out these investigations. The results of many of these investigations typically do not translate into a specific management strategy that makes a difference to prognosis. A significant number of children with DCM will eventually develop end-stage heart failure that requires cardiac transplantation with or without bridging procedures. This is an unrealistic option for the developing world. The management strategy of childhood DCM in the developing world needs to be tailored to the resources available with in a manner such that the overall prognosis is not substantially affected.

Management of cardiomyopathy resulting from incessant supraventricular tachycardia in infants and children.

BACKGROUND: Radiofrequency ablation is considered to be the treatment of choice in patients with ventricular dysfunction related to incessant supraventricular tachycardia. However, reservations regarding its use in infants and children prompted us to try alternative strategies for this group. METHODS AND RESULTS: Eight children (age range: 1 day to 10 years) were diagnosed to have tachycardia-related ventricular dysfunction in the past 6 years. They presented with symptoms of palpitation, dyspnea and/or generalized swelling over the body of 3 months to 2 years'duration. The cardiothoracic ratio at presentation was 64% (52%-70%) and ejection fraction was 22.2% (15%-45%). In 7 patients tachycardia was diagnosed to be ectopic atrial and in 1 it was permanent junctional reciprocating tachycardia. Six of these children were managed with intravenous/oral amiodarone in combination with digoxin (3) and/or propranolol (2). In one child addition of amiodarone to digoxin and propranolol led to polymorphic ventricular tachycardia, and amiodarone was withdrawn. Only one child underwent radiofrequency ablation as the first choice because regular follow-up was not possible due to logistic reasons. Sinus rhythm with normalization of ventricular function was achieved in 6 of the 7 children treated medically. One child continued to have frequent episodes of tachycardia and underwent successful radiofrequency ablation of a high right atrial ectopic focus. Two out of the 6 patients on amiodarone could be managed with only digoxin and propranolol after their ventricular function had returned to normal. A third patient relapsed on stopping amiodarone and underwent successful radiofrequency ablation of a left atrial ectopic tachycardia. CONCLUSIONS: Short-term amiodarone in combination with digoxin/propranolol is a safe and effective treatment strategy for infants/children with tachycardiomyopathy. Control of tachycardia is achieved in the majority, leading to recovery of ventricular function. This approach may avoid unnecessary ablations in children or at least postpone it till the procedure would be safer.

Miocardiopatía en embarazo / Myocardiopathy in pregnancy

Se reporta el caso clínico de una adolescente de 14 años de edad, previamente sana, primigesta de 20 semanas de gestación con historia de disnea y fatiga a esfuerzos moderados. La ecocargiografía muestra mala función ventricular izquierda con una fracción de eyección de 46 por ciento diagnosticándose cardiomiopatía dilatada. Llega a embarazo de término con tratamiento de digoxina y régimen hiposódico. Se interrumpe vía cesárea de urgencia con anestesia peridural por alteración mayor de la función ventricular izquierda en ecocardiografía de control. Se realiza la intervención con monitorización invasiva por medio de catéter venoso central y arterial periférico y uso de drogas inotrópicas de soporte. El postoperado cursa sin complicaciones en Unidad de Cuidados Intensivos. Un trabajo multidisciplinario coordinado tanto en el manejo como en la interrupción exitosa de la gestación, debe ser considerado

Reversäo e manutençäo do ritmo sinusal ou controle da resposta ventricular na fibrilaçäo atrial / Atrial fibrilation: reversion and maintenance of sinus rhythm or rate control

Duas estratégias farmacológicas têm sido propostas para o tratamento da fibrilaçäo atrial: a reversäo e manutençäo do ritmo sinusal com drogas antiarritmicas ou o controle da resposta ventricular associado ao emprego de anticoagulante oral. Até que se conheçam os resultados de alguns ensaios randomizados em andamento, comparando estas duas estratégias, a conduta mais adequada parece ser: 1) restaurar o ritmo sinusal, sem utilzaçäo de drogas antiarritmicas profiláticas após oum primeiro episódio de fibrilaçäo atrial, particularmente nos pacientes sem cariopatia; 2) manter o ritmo sinusal com drogas antiarritmicas nos pacientes com crises recorrentes, instabilidade hemodinâmica ou cardiopatia estrutural moderada e grave; 3) controlar a resposta ventricular e prevenir a ocorrência de eventos tromboembólicos, por meio de terapia anticoagulante em pacientes com fibrilaçäo atrial crônica e baixa probabilidade de manutençäo do ritmo sinusal (diâmetro do átrio esquerdo maior que 6,0 cm, fibrilaçäo atrial de longa duraçäo e resistência a vários antiarritmicos.

Flutter auricular crónico: una manifestación infrecuente de enfermedad del nódulo sinusal: caso clínico / Chronic atrial flutter as an infrequent manifestation of sick sinus syndrome: report of 1 case

We report a 41 years old female, previously operated of an atrial septal defect, presenting with a persisting atrial flutter. Sinus node dysfunction became evident during an electrophysiological study at the moment of interrupting the flutter with electrical stimulation. The patient was treated with his bundle ablation and implantation of a definitive pacemaker. After one year of follow up, she is devoid of symptoms